Qualified from Cambridge and St Bartholomew's Hospital 1971. Postgrad posts at UCLH, St Barts, Harvard Med School, Hammersmith Hospital and the Royal Marsden. A consultant here since 1981 and Professor of Cancer Medicine since 2002. MD Thesis ( Cantab ) 1977. Author of " Cancer and its Management ", a standard international text, now in its 6th Edn, and six other books, two for the general public. Board member of Cancer Research-UK since 1991. Previous member of the BMJ Ethics Cttee and previous Clinical Director of Oncology at UCLH, 1992- 1998. Past President of the Brit Assn for Head and Neck Oncology.
Breast cancer, myeloma, gynaecological and upper gastro-enterological cancers.
Multiple papers on innovative techniques of treatment for breast cancer, lung, head and neck and g-i cancers, ethics of innovative treatments. Various textbooks. Fuller listing in " Who's Who " 2010.
Most recent original research papers include :
1.Long-term Results of Targeted Intraoperative Radiotherapy (Targit) Boost during Breast-conserving Surgery.
Vaidya JS, Baum M, Tobias JS, et al. Int J Radiat Oncol Biol Phys. 2010 Oct 15. [Epub ahead of print]
2.The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol.
Duffy S, Jackson TL, Lansdown M, Philips K, Wells M, Clack G, Bianco AR et al, for the ATAC Trialists' Group.
J Obstet Gynaecol. 2010;30(6):596-604.
3.Targeted Intraoperative Radiotherapy for Breast Cancer in Patients in Whom External Beam Radiation Is Not Possible.
Keshtgar MR, Vaidya JS, Tobias JS, et al. Int J Radiat Oncol Biol Phys. 2010 Jun 18. [Epub ahead of print]
4.Response to "Intraoperative radiotherapy in early-stage breast cancer: results of the Montpellier phase II trial."(Int J Radiat Oncol Biol Phys May 2009).
Vaidya JS, Tobias JS, Baum M, Keshtgar M, Williams N, Wenz F, Joseph D.
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1289; author reply 1289.
5.Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial.
Vaidya JS, Joseph DJ, Tobias JS, et al. Lancet. 2010 Jul 10;376(9735):91-102.
6.Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial.
Tobias JS, Monson K, Gupta N, Macdougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A; UK Head and Neck Cancer Trialists' Group.
Lancet Oncol. 2010 Jan;11(1):66-74. Epub 2009 Oct 29.
7.Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.
Pignon JP, le Maître A, Maillard E, Bourhis J et al for the MACH-NC Collaborative Head and Neck Cancer Group.
Radiother Oncol. 2009 Jul;92(1):4-14. Epub 2009 May 14.